Selepressin (INN) (code name FE-202158), also known as [Phe(2),Ile(3), Hgn(4),Orn(iPr)(8)]vasopressin) is a potent, highly selective, short-acting peptide full agonist of the vasopressin 1A receptor and analog of vasopressin which was under development by Ferring Pharmaceuticals for the treatment of vasodilatory hypotension in septic shock.

[1][2][3][4] The Phase 2b/3 adaptive trial (SEPSIS-ACT) was terminated in February 2018 for futility.

The trial was halted prior to the initiation of the arm for the highest dosing regimen of 5.0 ng/kg/min.

[5] This hormonal preparation article is a stub.

You can help Wikipedia by expanding it.